Katalin Dobra
Professor/Senior Physician
E-mail: katalin.dobra@ki.se
Visiting address: BioClinicum Visionsgatan 4, 17176 SOLNA
Postal address: K7 Onkologi-Patologi, K7 Forskning Dobra, 171 77 Stockholm
About me
- I am Senior Physician and Professor of Clinical Pathology at the Department of Oncology-Pathology.
Research
- My research is about cancer of the lungs and pleurae – diseases that generally have a poor prognosis. In my research group, we study both primary cancer and metastases and our long-term goal is to help cancer patients obtain earlier and more accurate diagnoses and prognoses so that they can be given personalised treatment. The research spans the mapping of fundamental mechanisms of tumour growth to the development of new analytical methods and biomarkers.
I have a particular interest in the protein syndecan 1, which, in being involved in cell division, is relevant to tumour growth. The protein is anchored to the cell membrane, but we have made the surprising discovery that it is also found in the nucleus. We have also shown that soluble syndecan 1 in bodily fluids can be used as a biomarker for identifying aggressive tumours requiring more extensive treatment.
Articles
- Article: CANCERS. 2025;17(14):2363Hutyra-Gram Otvos R; Krynska H; Gudoityte G; Skribek M; Oniscu A; Berkovska O; Strauss K; Zipprick J; Tamborero D; Alexeyenko A; Gad AKB; Seashore-Ludlow B; Dobra K
- Article: APMIS. 2025;133(3):e70006Prabhakaran S; Hocking AJ; Irani Y; Hussey M; Alexeyenko A; Dobra K; Micsik T; Duhig E; Walts AE; Vanwalleghem L; Chhut V; Roden AC; Roggli VL; Hertoghs M; Galateau-Salle F; Brcic L; Moffat D; Klebe S
- Article: CANCERS. 2024;17(1):81Rosier M; Krstulovic A; Kim HR; Kaur N; Enakireru EM; Symmes D; Dobra K; Chen R; Evans CA; Gad AKB
- Article: HAEMATOLOGICA. 2023;108(9):2422-2434Hagey DW; Kvedaraite E; Akber M; Goergens A; Javadi J; Greenwood TVB; Bjorklund C; Akefeldt SO; Hannegard-Hamrin T; Arnell H; Dobra K; Herold N; Svensson M; El Andaloussi S; Henter J-I; Lourda M
- Article: CYTOPATHOLOGY. 2023;34(5):456-465Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnstrom H
- Article: CANCER MEDICINE. 2023;12(5):5334-5340Hjerpe A; Demir E; Abd-Own S; Dobra K
- Journal article: REVISTA CHILENA DE LITERATURA. 2023;(108):2422-2434Hagey DW; Kvedaraite E; Akber M; Gorgens A; Javadi J; Greenwood TVB; Bjorklund C; Akefeldt SO; Hannegard-Hamrin T; Arnell H; Dobra K; Herold N; Svensson M; El Andaloussi S; Henter J-I; Lourda M
- Article: JOURNAL OF CLINICAL PATHOLOGY. 2022;75(5):302-309Lindquist KE; Ciornei C; Westbom-Fremer S; Gudinaviciene I; Ehinger A; Mylona N; Urdar R; Lianou M; Svensson F; Seidal T; Haglund F; Dobra K; Bendek M; Bardoczi E; Szablewska A; Witkowski M; Ramnefjell M; De las Casas LE; Gulyas M; Hegedus A; Micke P; Brunnstrom H
- Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(9):4517Mansour MSI; Malmros K; Mager U; Lindquist KE; Hejny K; Holmgren B; Seidal T; Dejmek A; Dobra K; Planck M; Brunnstrom H
- Article: BIOMOLECULES. 2021;11(11):1721Ericson Lindquist K; Gudinaviciene I; Mylona N; Urdar R; Lianou M; Darai-Ramqvist E; Haglund F; Bendek M; Bardoczi E; Dobra K; Brunnstroem H
- Article: BIOMOLECULES. 2021;11(11):1606Javadi J; Goergens A; Vanky H; Gupta D; Hjerpe A; EL-Andaloussi S; Hagey D; Dobra K
- Article: BIOLOGY-BASEL. 2021;10(6):521Kumar-Singh A; Parniewska MM; Giotopoulou N; Javadi J; Sun W; Szatmari T; Dobra K; Hjerpe A; Fuxe J
- Article: PATHOLOGY. 2021;53(4):446-453Klebe S; Nakatani Y; Dobra K; Butnor KJ; Roden AC; Nicholson AG; Marchevsky AM; Husain AN; Segal A; Walts AE; Weynand B; Michael CW; Dacic S; Godbolt D; Attanoos R; Santoni-Rugiu E; Galateau-Salle F; Hiroshima K; Moreira AL; Burn J; Nabeshima K; Gibbs AR; Churg A; Litzky LA; Brcic L; Tsao MS; Mino-Kenudson M; Rorvig SB; Tazelaar HD; Krausz T; Zhang YZ; Chirieac LR; Beasley MB; Hjerpe A
- Article: CANCER CYTOPATHOLOGY. 2021;129(6):468-478Mansour MSI; Seidal T; Mager U; Dobra K; Brunnstrom H; Dejmek A
- Article: DIAGNOSTIC CYTOPATHOLOGY. 2021;49(5):606-614Abd Own S; Hoijer J; Hillerdahl G; Dobra K; Hjerpe A
- Article: CANCERS. 2021;13(4):685Keller M; Reis K; Hjerpe A; Dobra K; Aspenstrom P
- Article: CANCERS. 2021;13(4):655Javadi J; Heidari-Hamedani G; Schmalzl A; Szatmari T; Metintas M; Aspenstrom P; Hjerpe A; Dobra K
- Article: ONCOTARGET. 2020;11(50):4637-4647Reis K; Arbiser JL; Hjerpe A; Dobra K; Aspenström P
- Article: BIOMOLECULES. 2020;10(8):E1113-1113Javadi J; Dobra K; Hjerpe A
- Article: BIOMOLECULES. 2020;10(7):E1034-1034Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in Mesothelioma CellsKumar-Singh A; Shrinet J; Parniewska MM; Fuxe J; Dobra K; Hjerpe A
- Article: LIVER INTERNATIONAL. 2019;39(2):382-388von Seth E; Ouchterlony H; Dobra K; Hjerpe A; Arnelo U; Haas S; Bergquist A
- Article: ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. 2018;142(8):893-901Hjerpe A; Abd-Own S; Dobra K
- Article: BMC CELL BIOLOGY. 2017;18(1):34Szatmari T; Mundt F; Kumar-Singh A; Mobus L; Otvos R; Hjerpe A; Dobra K
- Journal article: EURASIAN JOURNAL OF PULMONOLOGY. 2017;19(3):130-138Arslan S; Mundt F; Metintas S; Ak G; Dobra K; Hjerpe A; Metintas M
- Article: CANCER CYTOPATHOLOGY. 2017;125(12):908-917Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
- Journal article: JOURNAL OF THORACIC ONCOLOGY. 2017;12(11):s2021Mansour M; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
- Article: ONCOTARGET. 2017;8(47):82885-82896Hillerdal C-O; Otvos R; Szatmari T; Abd Own S; Hillerdal G; Dackland A-L; Dobra K; Hjerpe A
- Article: MATRIX BIOLOGY. 2017;59:3-22Karousou E; Misra S; Ghatak S; Dobra K; Goette M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
- Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):295Robles AI; Olsen KS; Tsui DWT; Georgoulias V; Creaney J; Dobra K; Vyberg M; Minato N; Anders RA; Borresen-Dale A-L; Zhou J; Saetrom P; Nielsen BS; Kirschner MB; Krokan HE; Papadimitrakopoulou V; Tsamardinos I; Roe OD
- Journal article: PLEURA AND PERITONEUM. 2016;1(3):119-133Szulkin A; Szatmari T; Hjerpe A; Dobra K
- Article: CLINICAL NUCLEAR MEDICINE. 2016;41(4):263-267Uhlen N; Grundberg O; Jacobsson H; Sundin A; Dobra K; Sanchez-Crespo A; Axelsson R; Kolbeck K-G
- Article: CELLULAR SIGNALLING. 2015;27(10):2054-2067Heidari-Hamedani G; Vives RR; Seffouh A; Afratis NA; Oosterhof A; van Kuppevelt TH; Karamanos NK; Metintas M; Hjerpe A; Dobra K; Szatmari T
- Article: CANCER CYTOPATHOLOGY. 2015;123(8):449-453Hjerpe A; Dobra K
- Article: DIAGNOSTIC CYTOPATHOLOGY. 2015;43(7):563-576Hjerpe A; Ascoli V; Bedrossian CWM; Boon ME; Creaney J; Davidson B; Dejmek A; Dobra K; Fassina A; Field A; Firat P; Kamei T; Kobayashi T; Michael CW; Onder S; Segal A; Vielh P
- Article: GENES AND CANCER. 2015;6(3-4):119-128Ötvös R; Szulkin A; Hillerdal C-O; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Székely L; Dobra K
- Journal article: BIOMED RESEARCH INTERNATIONAL. 2015;2015:482879-2Skandalis SS; Dobra K; Goette M; Karousou E; Misra S
- Article: ACTA CYTOLOGICA. 2015;59(1):2-16Hjerpe A; Ascoli V; Bedrossian CWM; Boon ME; Creaney J; Davidson B; Dejmek A; Dobra K; Fassina A; Field A; Firat P; Kamei T; Kobayashi T; Michael CW; Onder S; Segal A; Vielh P
- Article: BMC CANCER. 2014;14:709Szulkin A; Otvos R; Hillerdal C-O; Celep A; Yousef-Fadhel E; Skribek H; Hjerpe A; Szekely L; Dobra K
- Article: MOLECULAR & CELLULAR PROTEOMICS. 2014;13(3):701-715Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtio J; Hjerpe A
- Article: BIOMED RESEARCH INTERNATIONAL. 2014;2014:419853-11Mundt F; Heidari-Hamedani G; Nilsonne G; Metintas M; Hjerpe A; Dobra K
- Article: PLOS ONE. 2013;8(8):e72030Mundt F; Nilsonne G; Arslan S; Csuros K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
- Article: PLOS ONE. 2013;8(6):e65903Szulkin A; Nilsonne G; Mundt F; Wasik AM; Souri P; Hjerpe A; Dobra K
- Article: FRONTIERS IN ONCOLOGY. 2013;3:203Darai-Ramqvist E; Nilsonne G; Flores-Staino C; Hjerpe A; Dobra K
- Article: PLOS ONE. 2012;7(10):e48091Szatmari T; Mundt F; Heidari-Hamedani G; Zong F; Ferolla E; Alexeyenko A; Hjerpe A; Dobra K
- Article: PLOS ONE. 2012;7(8):e40521Roe OD; Szulkin A; Anderssen E; Flatberg A; Sandeck H; Amundsen T; Erlandsen SE; Dobra K; Sundstrom SH
- Article: PLOS ONE. 2012;7(6):e39474Peterfia B; Fuele T; Baghy K; Szabadkai K; Fullar A; Dobos K; Zong F; Dobra K; Hollosi P; Jeney A; Paku S; Kovalszky I
- Article: JOURNAL OF IMMUNOLOGY. 2011;187(7):3546-3554Enqvist M; Nilsonne G; Hammarfjord O; Wallin RPA; Bjoerkstroem NK; Bjornstedt M; Hjerpe A; Ljunggren H-G; Dobra K; Malmberg K-J; Carlsten M
- Article: BMC CANCER. 2011;11:314Skandalis SS; Labropoulou VT; Ravazoula P; Likaki-Karatza E; Dobra K; Kalofonos HP; Karamanos NK; Theocharis AD
- Article: PLOS ONE. 2011;6(6):e14816Zong F; Fthenou E; Mundt F; Szatmari T; Kovalszky I; Szilak L; Brodin D; Tzanakakis G; Hjerpe A; Dobra K
- Article: INTERNATIONAL JOURNAL OF CANCER. 2010;127(9):1999-2008An Z; Dobra K; Lock JG; Stromblad S; Hjerpe A; Zhang H
- Article: LUNG CANCER. 2010;68(1):39-43Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
- Article: CELL PROLIFERATION. 2010;43(1):29-40Zong F; Fthenou E; Castro J; Peterfia B; Kovalszky I; Szilak L; Tzanakakis G; Dobra K
- Article: PLOS ONE. 2009;4(10):e7346Zong F; Fthenou E; Wolmer N; Hollosi P; Kovalszky I; Szilak L; Mogler C; Nilsonne G; Tzanakakis G; Dobra K
- Article: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2009;28(1):92Nilsonne G; Olm E; Szulkin A; Mundt F; Stein A; Kocic B; Rundlof A-K; Fernandes AP; Bjornstedt M; Dobra K
- Article: IN VIVO. 2009;23(1):69-76Fthenou E; Zong F; Zafiropoulos A; Dobra K; Hjerpe A; Tzanakakis GN
- Article: CONNECTIVE TISSUE RESEARCH. 2008;49(3-4):270-272Dobra K; Hjerpe A
- Article: CONNECTIVE TISSUE RESEARCH. 2008;49(3-4):249-251Hjerpe A; Dobra K
- Article: DIFFERENTIATION. 2007;75(2):123-132Rundlof A-K; Fernandes AP; Selenius M; Babic M; Shariatgorji M; Nilsonne G; Ilag LL; Dobra K; Bjornstedt M
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2006;281(46):35116-35128Theocharis AD; Seidel C; Borset M; Dobra K; Baykov V; Labropoulou V; Kanakis I; Dalas E; Karamanos NK; Sundan A; Hjerpe A
- Article: FREE RADICAL BIOLOGY AND MEDICINE. 2006;41(6):874-885Nilsonne G; Sun X; Nyström C; Rundlöf A-K; Potamitou Fernandes A; Björnstedt M; Dobra K
- Article: CANCER LETTERS. 2006;232(2):161-169Sun XJ; Gulyás M; Hjerpe A; Dobra K
- Article: JOURNAL OF PATHOLOGY. 2005;207(1):91-101Sun XJ; Wei L; Lidén J; Hui G; Dahlman-Wright K; Hjerpe A; Dobra K
- Article: ANTICANCER RESEARCH. 2004;24(2B):599-603Liu ZW; Dobra K; Hauzenberger D; Klominek J
- Article: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. 2004;34(4):797-801Seidel C; Gulyás M; David G; Dobra K; Theocharis AD; Hjerpe A
- Article: ANTICANCER RESEARCH. 2003;23(3B):2435-2444Dobra K; Nurminen M; Hjerpe A
- Article: ANTICANCER RESEARCH. 2002;22(6C):4157-4162Syrokou A; Dobra K; Tzanakakis GN; Hjerpe A; Karamanos NK
- Article: EXPERIMENTAL CELL RESEARCH. 2002;274(2):235-245Brockstedt U; Dobra K; Nurminen M; Hjerpe A
- Journal article: JOURNAL OF MUSCULOSKELETAL RESEARCH. 2001;5(02):79-88Dobra K; Hjerpe A
- Article: DIFFERENTIATION. 2000;66(4-5):181-188Sun XJ; Dobra K; Björnstedt M; Hjerpe A
- Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2000;114(2):203-209Brockstedt U; Gulyas M; Dobra K; Dejmek A; Hjerpe A
- Article: EXPERIMENTAL CELL RESEARCH. 2000;258(1):12-22Dobra K; Andäng M; Syrokou A; Karamanos NK; Hjerpe A
- Article: DIFFERENTIATION. 1999;65(2):89-96Gulyás M; Dobra K; Hjerpe A
- Show more
All other publications
- Preprint: BIORXIV. 2025Ivan ZZ; Hirling D; Grexa I; Ammeling J; Micsik T; Dobra K; Kuthi L; Farkas S; Aubreville M; Miczan V; Horvath P
- Review: CANCERS. 2025;17(6):986Zipprick J; Demir E; Krynska H; Kopruluoglu S; Strauss K; Skribek M; Otvos RH-G; Gad AKB; Dobra K
- Preprint: PREPRINTS.ORG. 2024Rosier M; Krstulović A; Kim HR; Kaur N; Enakireru EM; Symmes D; Dobra K; Chen R; Evans C; Gad A
- Book chapter: THE EXTRACELLULAR MATRIX AND THE TUMOR MICROENVIRONMENT: BIOLOGY OF EXTRACELLULAR MATRIX. 2022;p. 49-73Kovalszky I; Baghy K; Reszegi A; Hollósi P; Hjerpe A; Dobra K
- Review: ACTA CYTOLOGICA. 2021;65(6):501-509Mansour MSI; Lindquist KE; Seidal T; Mager U; Mohlin R; Tran L; Hejny K; Holmgren B; Violidaki D; Dobra K; Dejmek A; Planck M; Brunnstrom H
- Review: TRANSLATIONAL LUNG CANCER RESEARCH. 2020;9(3):934-943Hjerpe A; Own SA; Dobra K
- Review: CYTOPATHOLOGY. 2019;30(1):31-38Engels M; Michael C; Dobra K; Hjerpe A; Fassina A; Firat P
- Conference publication: JOURNAL OF HEPATOLOGY. 2018;68:S217von Seth E; Ouchterlony H; Haas S; Dobra K; Hjerpe A; Bergquist AM
- Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2017;12(11):S2020Mansour M; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
- Review: PLEURA AND PERITONEUM. 2016;1(3):119-133Szulkin A; Szatmári T; Hjerpe A; Dobra K
- Corrigendum: CELLULAR SIGNALLING. 2015;27(12):2599-2600Heidari-Hamedani G; Vives RR; Seffouh A; Afratis NA; Oosterhof A; van Kuppevelt TH; Karamanos NK; Metintas M; Hjerpe A; Dobra K; Szatmari T
- Review: CYTOJOURNAL. 2015;12:26Hjerpe A; Ascoli V; Bedrossian C; Boon M; Creaney J; Davidson B; Dejmek A; Dobra K; Fassina A; Field A; Firat P; Kamei T; Kobayashi T; Michael CW; Tnder S; Segal A; Vielh P
- Review: CYTOPATHOLOGY. 2015;26(3):142-156Hjerpe A; Ascoli V; Bedrossian CWM; Boon ME; Creaney J; Davidson B; Dejmek A; Dobra K; Fassina A; Field A; Firat P; Kamei T; Kobayashi T; Michael CW; Onder S; Segal A; Vie P
- Review: DISEASE MARKERS. 2015;2015:796052-13Szatmari T; Otvos R; Hjerpe A; Dobra K
- Review: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2014;1840(8):2491-2497Kovalszky I; Hjerpe A; Dobra K
- Review: FRONTIERS IN ONCOLOGY. 2013;3:310Szatmari T; Dobra K
- Meeting abstract: LUNG CANCER. 2006;54:S52Nilsonne G; Stein A; Rundloef A-K; Fernandes AP; Bjoernstedt M; Hjerpe A; Dobra K
- Conference publication: ANTICANCER RESEARCH. 2004;24(5D):3473Nilsonne G; Sun X; Nystrom C; Rundlof A-K; Nurminen M; Bjornstedt M; Dobra K
- Show more
Grants
- Syndecan-1 in cell surface and nucleus interconnects multiple signaling pathways in tumors, inhibits tumor growth and can be a useful biomarkerSwedish Cancer Society1 January 2018Proteoglycan syndecan-1 (sdc1) is a molecule in the cell membrane, where it manages cell interactions with its environment. Syndecan-1 is important for mesothelioma cell maturation, and is linked to good prognosis, while if it is cut from the cell surface due to various enzymatic reactions, mesothelioma cells become more aggressive and the prognosis deteriorates. We have found that sdc-1 can also be transported to the cell nucleus, where it inhibits the cell's growth and ability to move, which are central functions of cancer cells. We have mapped the Sdc-1 structure in detail and was able to identify a minimal structure sufficient to reduce cell growth. We test sdc1 as a diagnostic biomarker when analyzing both blood samples and fluid from the pulmonary sacs. To achieve clinical utility, sdc1 must be measured together with other markers. In a first sub-project, we will find out how cells with different levels of sdc1 in the nucleus differ and which substances interact with sdc1 in the cell nucleus. A short sequence of the sdc1 molecule RMKKK that directs it into the nucleus is tested as possible growth inhibitor. We also test if sdc-1 can participate in uptake of different drugs and if it is important for communication between cells through vesicular structures, so-called exosomes. When we have learned to better understand how sdc1 links different signal paths, it gives a basic knowledge of how different cell functions are regulated. It will then give us valuable tools to attack tumor cells. Sdc1 affects a number of growth factors against which there are specific chemo. Sdc1 can therefore be a molecule that can specifically mediate the treatment of tumors. The biomarker analysis aims to be able to diagnose malignant mesothelioma at an earlier stage and provide increased possibilities for cure for patients.
- Syndecan-1 links multiple signaling pathways in mesenchymal tumors and can be a useful biomarkerSwedish Cancer Society1 January 2017The proteoglycan syndecan-1 (sdc1) is a molecule in the cell membrane, where it manages the cell's interaction with its environment. We have found that it can also go to the cell nucleus, where it regulates the cell's growth and ability to move, which are central functions of cancer cells. During the fetus, the body's supporting tissues and epithelium develop. Sometimes the cells switch between these main groups, ie they can switch from connective tissue to epithelium (MET) and vice versa (EMT), a process called trans-differentiation. In the tumor malignant mesothelioma, this transdifferentiation can be induced in experiments, making it possible to study the process more closely. We test sdc1 as a diagnostic biomarker when analyzing both blood samples and fluid from the pulmonary sacs. To achieve clinical utility, sdc1 must be measured together with other markers. In a first sub-project, we will find out how cells with different levels of sdc1 in the nucleus differ and which substances interact with sdc1 in the cell nucleus. We will also study how the varying level of sdc1 in the core of mesothelioma cells affects the division of the cell, growth, motility and neovascularization. A short sequence of the sdc1 molecule that directs it into the nucleus is tested as possible growth inhibitor. When we learned to better understand how sdc1 links different signal paths, it gives a basic knowledge of how different cell functions are regulated. It will then include factors that can be attacked in malignant tumors. Sdc1 affects a number of growth factors against which there are specific chemo. Sdc1 can therefore be a molecule that can specifically mediate the treatment of tumors. The biomarker analysis aims to be able to diagnose malignant mesothelioma at an earlier stage and provide increased opportunities for curative treatment.
- Syndecan-1 links multiple signaling pathways in mesenchymal tumors and can be a useful biomarkerSwedish Cancer Society1 January 2016The proteoglycan syndecan-1 (sdc1) is a molecule in the cell membrane, where it manages the cell's interaction with its environment. We have found that it can also go to the cell nucleus, where it regulates the cell's growth and ability to move, which are central functions of cancer cells. During the fetus, the body's supporting tissues and epithelium develop. Sometimes the cells switch between these main groups, ie they can switch from connective tissue to epithelium (MET) and vice versa (EMT), a process called trans-differentiation. In the tumor malignant mesothelioma, this transdifferentiation can be induced in experiments, making it possible to study the process more closely. We test sdc1 as a diagnostic biomarker when analyzing both blood samples and fluid from the pulmonary sacs. To achieve clinical utility, sdc1 must be measured together with other markers. In a first sub-project, we will find out how cells with different levels of sdc1 in the nucleus differ and which substances interact with sdc1 in the cell nucleus. We will also study how the varying level of sdc1 in the core of mesothelioma cells affects the division of the cell, growth, motility and neovascularization. A short sequence of the sdc1 molecule that directs it into the nucleus is tested as possible growth inhibitor. When we learned to better understand how sdc1 links different signal paths, it gives a basic knowledge of how different cell functions are regulated. It will then include factors that can be attacked in malignant tumors. Sdc1 affects a number of growth factors against which there are specific chemo. Sdc1 can therefore be a molecule that can specifically mediate the treatment of tumors. The biomarker analysis aims to be able to diagnose malignant mesothelioma at an earlier stage and provide increased opportunities for curative treatment.
- Syndecan-1 links multiple signaling pathways in mesenchymal tumors and can be a useful biomarkerSwedish Cancer Society1 January 2015The proteoglycan syndecan-1 (sdc1) is a molecule in the cell membrane, where it manages the cell's interaction with its environment. We have found that it can also go to the cell nucleus, where it regulates the cell's growth and ability to move, which are central functions of cancer cells. During the fetus, the body's supporting tissues and epithelium develop. Sometimes the cells switch between these main groups, ie they can switch from connective tissue to epithelium (MET) and vice versa (EMT), a process called trans-differentiation. In the tumor malignant mesothelioma, this transdifferentiation can be induced in experiments, making it possible to study the process more closely. We test sdc1 as a diagnostic biomarker when analyzing both blood samples and fluid from the pulmonary sacs. To achieve clinical utility, sdc1 must be measured together with other markers. In a first sub-project, we will find out how cells with different levels of sdc1 in the nucleus differ and which substances interact with sdc1 in the cell nucleus. We will also study how the varying level of sdc1 in the core of mesothelioma cells affects the division of the cell, growth, motility and neovascularization. A short sequence of the sdc1 molecule that directs it into the nucleus is tested as possible growth inhibitor. When we learned to better understand how sdc1 links different signal paths, it gives a basic knowledge of how different cell functions are regulated. It will then include factors that can be attacked in malignant tumors. Sdc1 affects a number of growth factors against which there are specific chemo. Sdc1 can therefore be a molecule that can specifically mediate the treatment of tumors. The biomarker analysis aims to be able to diagnose malignant mesothelioma at an earlier stage and provide increased opportunities for curative treatment.
- Transdifferentiation of mesenchymal tumors; the importance of syndecan-1 in the cell surface and cell nucleusSwedish Cancer Society1 January 2014This project aims to study syndecan-1 as a possible biomarker and create an understanding of the process called transdifferentiation, where the proteoglycan syndecan-1 (sdc1) is an important co-player. During the fetal period, the body develops from three main types of tissue. One of these gives rise to the body's supporting tissues. During this development, the constituent cells are transformed, sometimes so as to switch appearance and function between the main groups, ie transitions from connective tissue to epithelium (MET) and vice versa (EMT). In the adult individual, such transdifferentiation can take place, for example, in tumors, where EMT causes a more difficult-to-treat condition with poorer prognosis. Sdc1 is a molecule in the cell membrane that manages the cell's interactions with its environment. A few years ago we showed that sdc1 also goes to the nucleus of the cell, and our preliminary results indicate that the one that regulates the cell's growth and ability to move, ie central functions for cancer cells. In these systems we will study more precisely which of the sdc1's functions are of importance for the mesothelioma cell transdifferentiation, which also gives knowledge of what makes that tumor so difficult to treat. We have recently been able to show that a short sequence of the sdc1 molecule is what directs it into the nucleus and it slows the growth of mesothelioma cells. We will study how mesothelioma cells with varying levels of sdc1 in the nucleus grow, divide and move. Of central importance to this project is also to link this to the cell's growth mode. This is done partly by showing with different antibodies markers for the different forms of the transdifferentiation. When we learned to better understand how transdifferentiation works, we gain through this important knowledge of malignant tumors that are used directly for diagnostic and treatment purposes. In pleural fluid and blood samples, syndecan-1 can be used to enable early diagnosis and thereby improve the patient's possibilities for successful treatment.
- Swedish Research Council1 January 2012 - 31 December 2014
Employments
- Professor/Senior Physician, Department of Oncology-Pathology, Karolinska Institutet, 2022-
Degrees and Education
- Docent, Karolinska Institutet, 2010
- Doctor Of Philosophy, Department of Laboratory Medicine, Karolinska Institutet, 2002